InnoPharmax Past Earnings Performance
Past criteria checks 0/6
InnoPharmax's earnings have been declining at an average annual rate of -3.6%, while the Pharmaceuticals industry saw earnings growing at 8.2% annually. Revenues have been declining at an average rate of 21.2% per year.
Key information
-3.6%
Earnings growth rate
2.6%
EPS growth rate
| Pharmaceuticals Industry Growth | 18.5% |
| Revenue growth rate | -21.2% |
| Return on equity | -19.3% |
| Net Margin | -241.5% |
| Last Earnings Update | 30 Jun 2024 |
Revenue & Expenses Breakdown
How InnoPharmax makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Jun 24 | 35 | -84 | 29 | 71 |
| 31 Mar 24 | 40 | -77 | 26 | 65 |
| 31 Dec 23 | 46 | -71 | 23 | 59 |
| 30 Sep 23 | 48 | -77 | 23 | 60 |
| 30 Jun 23 | 49 | -84 | 23 | 61 |
| 31 Mar 23 | 39 | -94 | 22 | 66 |
| 31 Dec 22 | 29 | -103 | 21 | 72 |
| 30 Sep 22 | 32 | -102 | 22 | 70 |
| 30 Jun 22 | 34 | -101 | 23 | 68 |
| 31 Mar 22 | 41 | -97 | 22 | 64 |
| 31 Dec 21 | 48 | -93 | 22 | 60 |
| 30 Sep 21 | 79 | -77 | 22 | 60 |
| 30 Jun 21 | 110 | -62 | 23 | 60 |
| 31 Mar 21 | 123 | -53 | 24 | 61 |
| 31 Dec 20 | 137 | -44 | 26 | 62 |
| 30 Sep 20 | 128 | -54 | 26 | 66 |
| 30 Jun 20 | 119 | -63 | 26 | 70 |
| 31 Mar 20 | 102 | -76 | 24 | 78 |
| 31 Dec 19 | 85 | -88 | 23 | 86 |
| 30 Sep 19 | 66 | -88 | 23 | 87 |
| 30 Jun 19 | 46 | -88 | 23 | 87 |
| 31 Mar 19 | 51 | -87 | 26 | 84 |
| 31 Dec 18 | 56 | -86 | 28 | 80 |
| 30 Sep 18 | 49 | -105 | 33 | 85 |
| 30 Jun 18 | 39 | -124 | 37 | 91 |
| 31 Mar 18 | 41 | -143 | 41 | 109 |
| 31 Dec 17 | 44 | -162 | 45 | 127 |
| 30 Sep 17 | 58 | -44 | 44 | 128 |
| 30 Jun 17 | 59 | -65 | 51 | 148 |
| 31 Mar 17 | 52 | -57 | 54 | 136 |
| 31 Dec 16 | 46 | -49 | 56 | 124 |
| 30 Sep 16 | 37 | -160 | 56 | 126 |
| 30 Jun 16 | 45 | -134 | 49 | 108 |
| 31 Mar 16 | 45 | -130 | 47 | 107 |
| 31 Dec 15 | 44 | -126 | 46 | 106 |
| 30 Sep 15 | 45 | -123 | 48 | 103 |
| 30 Jun 15 | 46 | -121 | 51 | 100 |
| 31 Mar 15 | 78 | -89 | 51 | 103 |
| 31 Dec 14 | 109 | -58 | 51 | 105 |
| 30 Sep 14 | 104 | -65 | 49 | 112 |
| 30 Jun 14 | 100 | -72 | 46 | 119 |
| 31 Mar 14 | 67 | -106 | 45 | 120 |
| 31 Dec 13 | 34 | -141 | 43 | 122 |
Quality Earnings: 4172 is currently unprofitable.
Growing Profit Margin: 4172 is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: 4172 is unprofitable, and losses have increased over the past 5 years at a rate of 3.6% per year.
Accelerating Growth: Unable to compare 4172's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: 4172 is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (17.2%).
Return on Equity
High ROE: 4172 has a negative Return on Equity (-19.26%), as it is currently unprofitable.